Replay available

Athenex (ATNX) Q3 2019 Earnings Call

Athenex (ATNX) Q3 2019 earnings call, held 2019-11-07. Watch the replay and read the transcript on 6ix.

Thu, November 7, 2019 at 8:00 AMendedReplay
Athenex (ATNX) Q3 2019 Earnings Call
Company
Athenex Inc
Period
Q3 2019 earnings call
Date
Thu, Nov 7, 2019, 8:00 AM ET
Replay
Watch the replay on this page · 58 min

On 6ix: 6ix.com/event/athenex-inc-atnx-q3-2019-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Greetings and welcome to the Athenix, Inc. third quarter 2019 earnings call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. Tim McCarthy, with LifeSci Advisors.

0:31 Please go ahead, sir. Good morning, and thank you for joining our conference call as we provide an update on the business, as well as a review of financial results for the third quarter of 2019. The news release detailing the third quarter results crossed the wire earlier this morning and is available on the company's website. A replay of this call will also be archived on the company website. During the course of this conference call, the company will make projections or forward-looking statements regarding future events, including statements about financial and clinical milestones anticipated in fiscal year 2019 and beyond. We encourage you to review the company's past and future filings with the SEC, which identify specific factors that may cause the actual results or events to differ materially from those described in the forward-looking statements.

1:16 You can find our SEC filings in the EDGAR database at sec.gov or in the investor relations section at our website at athenx.com. This morning we are joined by Dr. Johnson Lau, Chief Executive Officer, Mr. Jeff Yorden, Chief Operating Officer, Dr. Rudolph Kwan, Chief Medical Officer, Mr. Randall Zee, Chief Financial Officer, and several other executives who will be available to answer questions after the prepared remarks. With that, I'll turn the call over to Johnson for introductory comments.

1:47 Thank you, Tim. Hello and welcome. We have continued to make strong progress across the board, bringing us closer to becoming a fully integrated global pharmaceutical company. For the second time this year, we are pleased to be raising full-year product sales guidance for 2019. We have several major catalysts upcoming, including an oral presentation of Oropraclitaxel and Ensequadar data at the upcoming San Antonio Breast Cancer Meeting and two anticipated end-day findings in early 2020, which we expect to follow with regulatory findings in additional global markets. We are also in a very strong position to advance multiple potentially successful therapies in the future.

2:37 will have been strategic in building out our operations and managing our resources to maximize the potential commercial opportunity of drug candidates in development. As our broader pipeline continues to advance, we're looking beyond current indications and for ways to get the best labels and marketing outcomes for our products. As we prepare to market our first proprietary oncology drug, Oroplactaxel and Ensequadar, will make significant progress to expand and optimize our commercial infrastructure. We expect to be well prepared to make a significant impact with this product immediately once it's approved. As our Chief Operating Officer, Mr. Jeff Yoden will discuss A major part of our ongoing commercial preparation is to continue raising the profile of our new Afinex Oncology brand and become a recognized commercial player with differentiated products that target cancer.

3:42 Oropracotexil will become our flagship product to build our global brand upon approval. Currently, we are preparing to discuss the Phase III data with the FDA who previously indicated that this study, if successful, could be adequate as a single comparative trial to support registration of oral Prachetaxel and Enzequeda in the U.S. for metastatic breast cancer. The positive data we reported in August was a major milestone for ePhenX, adding to the strong body of clinical evidence that our oral scuffery platform is working as designed. This significantly de-risked the clinical programs that followed, including oral docetaxel, oral erythrotecan, oral topotecan, and oral erubilin.

4:37 Based on the successful outcome of the Phase III study, oral placatexel has demonstrated a very strong clinical profile from both efficacy and safety perspectives. The study met its primary endpoint, showing statistically significant improvement in O4 response rate compared to IV Precatexol. There were also strong trends in progression-free survival and O4 survival of oral Precatexol compared to IV Precatexol, as well as a greater proportion of confirmed responders on oral Precatexol with duration of response greater than 150 days versus IV Precatexol. neuropathy was much less frequent with oroprexatexor, which we believe is an important differentiating factor.

5:30 Importantly, this clinical outcome highlights the potential of our oral chemotherapy pipelines, which we expect to develop for a range of cancers and combination approaches, as part of product lifecycle management. Our second NDA, is for our terminobulin ointment for treating adenine keratosis, for which we report positive phase III top-line results in March this year. We completed pre-ended consultation with the FDA and are in the process of finalizing the submission with an anticipated filing in the first quarter of 2020. Our partner, Emerald, is also preparing to submit the market authorization application in Europe.

6:19 We and our partner Emerald are very excited to launch this product for patients with actinic keratosis who are in serious need of effective therapy. Under our agreement with Emerald, we are eligible for development and sales milestone payments and commercial royalties. I also want to highlight our ongoing effort to integrate our core functions and capture value across the supply chain. I'm very pleased that Affinex has continued to expand our global capabilities and footprint, both in terms of clinical and manufacturing, for our proprietary products and for our customers around the world, which Jeff will discuss. Our new and larger API plant in China completed construction and is anticipated to commence operation in first half of next year.

7:14 We have also expanded our global clinical R&D capacity in Europe with the establishment of a subsidiary in the UK, and we are growing the number of trial sites in the region. And we are delighted to report that the acquisition of Seidel Assets in Latin America closed on October 31st. These initiatives have been taken with the goal of enhancing a Phoenix's capacity to conduct clinical studies and support our regional marketing decision process. Competition for patients globally has become fierce. Having a high-quality Latin American clinical operation allows us to draw from a population for clinical development that's been overlooked by traditional big pharma. Moreover, Many of our new colleagues at Seidel were, in fact, trained by U.S. big pharma companies, so they bring strong expertise.

8:14 Because of this enhanced global infrastructure, we believe we'll be in a position to deliver substantial growth and maximum value over the years to come. On the management front, during the quarter, we announced the appointment of Dr. Daniel Lang as President of Access Ferritics Ltd. to lead the operations of our T-cell immunotherapy platform and also act as the City Director of Corporate Development for Infinex. Dr. Leng was previously the Chief Investment Officer of RS Investments. He has over 25 years of medicine, healthcare investment, as well as leadership and business experience. We're delighted to welcome him and look forward to his leadership and insight Inc. Inc. Inc. Inc.

9:32 Inc. Inc. Inc. Inc. At this point, we do not intend to comment further on this subject, as we want to put our focus on what really matters, which is our pipeline value, clinical developments, and business progress. I will now turn the call over to our Chief Medical Officer, Dr. Rudolph Kwan, to provide an overview of our clinical programs.

10:17 Rudolph?

10:19 Thank you, Johnson. We are moving ahead confidently towards our first NDA submission for our oral discovery platform based on the strong data we previously reported for our lead candidate, oral Placatexel plus Encequeda. As a reminder, the randomized multi-center study involved 402 patients and compared our product to intravenous Placatexel in patients with confirmed metastatic breast cancer and for home Placatexel monotherapy is recommended. We were very excited to announce that the study matched its primary endpoint, showing statistically significant improvement over IV Placatexel in confirmed overall tumor response rate. Based on ITT analysis, oral Placatexel showed an overall response rate of 36% compared to 24% for IV Placatexel patients.

11:22 This endpoint was based on the research 1.1 criteria with a p-variable of 0.01. There was also benefit in terms of duration of response. As we detailed on our last call, we also saw strong trends for both progression-free survival and overall survival that favored oral Placatexel. We are also very pleased with the safety profile for oral Placatexel. In particular, we saw much lower neuropathy compared to IV placatexel, 17% versus 57% overall, and for grade three neuropathy, 1% versus 8%.

12:10 Neuropathy is the major dose-limiting toxicity for IV placatexel treatment and can be chronic and irreversible. Collectively, the results of this pivotal study represent an important milestone in the development of this new class of oral anti-cancer drugs. Based on the Phase III results, we see compelling evidence in terms of the efficacy and safety of Oropraclitaxel's clinical benefit for patients with metastatic breast cancer. We believe it will be competitive and has the potential to become a cornerstone in the treatment of metastatic breast cancer. As we disclosed, we are scheduled to deliver an oral presentation of our phase three results at the St. Antonio Breast Cancer Symposium on December the 13th.

13:05 We plan to share additional information around the top line efficacy and safety results that we reported in August. We believe the physician community will find the data compelling and look forward to this important update. In the meantime, we are currently working diligently to complete our NDA submission for oral Placatexel, which we currently expect in the first quarter of next year. We expect to provide another update after the NDA has been filed. Importantly, we believe this is only the beginning in terms of the value we expect to demonstrate for oral Placatexel and our oral discovery platform. We have also shown high response rates and a strong safety profile for oral plucatexel in unresectable cutaneous angiosarcoma and gastric cancer in combination with remesirumab.

14:04 With respect to the angiosarcoma program, part two of the study has commenced and is continuing to enroll well after observing rapid and robust tumor response in part one. We are planning to expand the study to the UK and other countries. We were pleased to announce last week that we received orphaned destinations from the European Commission for Prachatexel and Secuadol in the treatment of soft tissue sarcoma. In terms of future opportunities for this product, we are working to develop oral Prachatexel for additional indications and are exploring potential combinations with biologics. For example, anti-PD-1, anti-VGF therapies.

14:52 Our Phase I-II study of oral plaketaxel in combination with pembrolizumab or Cachuda is enrolling well. We are also advancing in the expansion phase of our global Phase I-B study of oral plaketaxel and encephalodon with remesirumab in patients with advanced gastric cancer. We recently presented encouraging results from this study at the ESMO Congress 2019. Looking to our other Phase III program, Turbanipaline ointment for treating adenocaritosis, we are pleased to update that we have recently completed pre-NDA consultation with the US FDA and are on track with the preparation of the NDA submission, which is expected to be filed in the first quarter of 2020.

15:44 We continue to believe that Turbulin's clean safety profile and high clearance rates, as observed in the Phase III studies, confer a competitive advantage over existing therapies for AK, which are limited by side effects that negatively impact patient compliance. So we look forward to bringing this variable treatment option to the market, and Jeff will talk more about that. Now turning briefly to our early stage clinical programs. This quarter, we announced that our partner, Sanjay Pharmaceutical, initiated a phase one study of oral KX2361, formerly known as KXO2.

16:30 KX2361 is being developed to treat glioblastoma multiforme, or GBM, due to its unique ability to cross a blood-brain barrier. Treatments are very limited for GBM, so KX2361 could become a potentially variable treatment option for patients who have high unmet needs. In summary, we are proud of the progress being made across our R&D pipeline, and we are continuing to execute on all the clinical programs. We look forward to presenting further updates in the future. With that, I'll turn the call to our Chief Financial Officer, Randall Z.

17:15 Randall?

17:17 Thank you, Rudolph. Product sales for the three months ended September 30, 2019, were $19.2 million, compared with $13.3 million for the three months ended September 30, 2018, an increase of 45% year-over-year. This increase was primarily attributable to an increase in specialty product revenue, and 503b revenue of $4.7 million and $2.5 million, respectively. The licensing fees and consulting revenues for the three-month end of September 30, 2018 were primarily in relation to the license agreement that we have entered into with AMRO. Cost of sales for the three-month end of September 30, 2019 totaled $17.1 million, an increase of $5.1 million, or 43%.

18:09 as compared to $12 million for the three months end of September 30, 2018. This was primarily due to the increase of $4.9 million in cost of sales resulting from the sale of specialty products. The increase in cost of sales was generally in line with product sales increase. Research and development expenses for the three months end of September 30, 2019 were $19.6 million as compared to $51.2 million for the three months ended September 30, 2018. The decrease in R&D expenses was primarily due to a decrease in licensing fees for technology we acquired in July 2018. We booked a non-cash license fee of $29.5 million in the three months ended September 30, 2018, and it was related to the purchase of the TCRT technology in connection with the establishment of SS Therapeutics.

19:09 Selling general and administrative expenses for the three months ended September 30, 2019, totaled $16.3 million, as compared to $11.5 million for the three months ended September 30, 2018. This was primarily due to an increase in cost of preparing to commercialize our proprietary drugs, an increase in general administrative expenses, including legal fees and other professional service fees. Net loss attributable to Ethnex for the three months end of September 30, 2019 was $34.8 million, or $0.45 per diluted share, compared to a net loss of $46.2 million, or $0.70 per diluted share in the same period last year.

19:59 We received a $20 million milestone payment from Amro during the second quarter of 2019 in connection with the partnership on Turban Nebulon and expect this payment to be recorded as revenue in the fourth quarter of 2019. At September 30, 2019, the company had cash, cash equivalents, restricted cash, and short-term investments of $129.2 million compared to $107.4 million at December 31, 2018. Based on the current operating plan, we expect our cash, cash equivalents, and restricted cash as of September 30, 2019, together with cash to be generated from our operating activities, will enable us to fund our operations into the third quarter of 2020. We provide revenue guidance for product sales only.

20:53 Today, we are raising our product sales guidance for the full year 2019 to an increase of 35% to 40% year-over-year from 56.4 million in 2018. This is versus prior guidance of 30% to 35% year-over-year, and this is on top of the previous guidance increase we made in August. This new revenue guidance has taken into account the discontinuation of our visual presence sales and the suspension of operations at our Tai Hao API plant. This revenue guidance excludes license and collaboration fees. For more detailed discussion on our financials, including those specific factors that contributed to the changes in line items on our income statement, as well as financial results for the nine months and September 30, 2019, please refer to the Form 10-Q to be filed with the SEC.

21:50 I will now turn the call next to Jeff Yordan.

21:57 Thank you. As our regulatory and clinical teams work to prepare for NDA submissions for our two lead product candidates, we have continued to expand and optimize our commercial infrastructure and develop the market in anticipation of commercial launch of oral paclitaxel. We plan to be prepared to capture significant market share as efficiently as possible, establishing this product as the chemotherapy of choice for metastatic breast cancer. As we have discussed, Tim Cook, our Senior VP of Marketing, has begun assembling his team of highly accomplished executives to lead our commercialization efforts.

22:44 We've now finalized our staffing and organizational plan and will begin to make additional key hires in early 2020, including medical science liaisons and regional sales leaders with the full sales team coming on board in the months leading up to potential approval. We have also continued our discussions with experts in the areas of access, distribution, and patient adherence to further understand the market dynamics for metastatic breast cancer that will drive our success upon potential approval. We are conducting payer market research and happy to see a strong positive response to the unique product profile of our oral Paclitaxel candidate.

23:36 We are also working to refine the specific target physician and patient segments so we can have a focused promotion of the product at launch. we're expecting to target physicians and patients who are early adopters of new therapies, supportive of an oral option, and patients that are generally hands-on in terms of working with their doctors to find the right treatment for them. As highlighted, the next key event for us will be the San Antonio Breast Cancer Symposium, where we will have a substantial presence. In addition to the presentation on the oral paclitaxel and Inseclidor Phase III results, San Antonio will be an opportunity to continue the efforts introduced at ASCO earlier this year and generate further awareness and interest in the Athenix Oncology brand.

24:34 Our activities around the meeting are designed to ensure strong presence and visibility with KOLs and provide concrete signals of our long-term commitment to oncology. Specifically, we plan to launch our new campaign, Empowered, the theme of which is empowering patients and why it's at the heart of everything MetaPhoenix does. As with ASCO, we will have a booth staffed with medical affairs and commercial personnel, as well as initiatives, including a full-page program ad to drive attendees to our booth and our website. We look forward to seeing some of you in San Antonio. I would encourage you to visit our booth.

25:21 In parallel with our efforts around oral paclitaxel and Ensecador, we are preparing to submit the NDA for turbanobulin ointment in the U.S. As Johnson mentioned, we remain on track to file the NDA. Turbanobulin ointment is a novel treatment for actinic keratosis, which is terribly underserved market. Upon approval, Amaral will lead the commercialization efforts for the U.S. as well as Europe. As announced by Amaral, product launches in the U.S. and in Europe are expected in Q1 2021 and Q2 2021, respectively. Athenix retains the right for Turbanobulin in significant global markets such as Japan, Canada, Australia, Israel, and several Asian markets.

26:14 to access these markets in collaboration with regional partners or directly with our own resources, depending on the market conditions and the early commercial experience for Durban Abulin in the United States. In addition to this late-stage pipeline progress, we are once again pleased to report strong revenue growth for our existing commercial business. As Randall mentioned, Our product revenue for Q3 beat our projections, and this was driven by new and recently launched products, which were led by Lipothyroxine. APD currently markets 31 products with 59 SKUs.

26:59 APS markets five products with 13 SKUs. In the third quarter, we launched one new product with the goal of launching a total of three to five new products in the remainder of 2019. As we discussed, the litigation regarding vasopressin was not decided in a Phoenix's favor. While this was a disappointing result, it was certainly not unexpected, and we have now discontinued the litigation proceedings and ceased marketing vasopressin. Vasopressin was a significant driver of revenue growth in 2018 and has also been a contributor to 2019.

27:46 We will continue to seek opportunities to add to our portfolio of specialty pharmaceutical and 503 products in order to drive further growth and leverage the brand recognition and relationships we have built in oncology. On the manufacturing front, Work continues on building our New York State-funded production plant in Dunkirk, New York, which we continue to anticipate becoming operational in the second half of 2021. Once it is online, we will begin with CGMP commercial manufacturing of our injectable and 503B products, and eventually our proprietary oncology products as well. Exterior construction is of the 409,000 square foot plant is complete and we are well on our way with the interior construction with the expectation that we'll order the filling equipment late this year or early next year. We look forward to completing construction and bringing this facility online.

28:54 XUS, we announced in September that we completed construction of our new 440,000-square-foot API facility in Chongqing, China, significantly expanding our API production capacity to support our global clinical development needs and ensure an uninterrupted supply of API to support our future commercial launches. The opening of this facility is part of the Themis's ongoing strategy for vertical integration in order to capture value across the entire supply chain. The facility will be producing validation batches, and we expect to commence operations in the first half of 2020.

29:41 As you may recall, in the second quarter of 2019, we decided to suspend operations at our current manufacturing facility in Chongqing, China, after a few incidents occurred at unrelated facilities in the region. However, we believe we will be able to support the requirements for Athenix's ongoing near-term clinical studies and registration activities for late-stage clinical products, and we have taken steps to secure additional backup sources. We will provide an update in due course. So, to summarize, we've continued to execute successfully across all of our strategic objectives with respect to our commercial preparedness, vertical integration.

30:32 We're continuing to leverage broad opportunities, establish our global oncology brand, and build out our marketing infrastructure. We're actively developing the market and honing our sales strategy in advance of the anticipated product launch for oral papitaxel and Insecadar. Based on the positive feedback and progress we've made to date, we expect to hit the ground running as soon as the first product is approved. I will now turn the call back to Johnson Lau for his wrap-up.

31:08 Thank you. We remain on track to make 2019 a transformational year for ePhenX, which we believe will position the company as a global leader in oncology. And as we advance towards two ND filings in the coming months, we're looking to 2020 to be another important year of growth. We're actively preparing for the exciting opportunities ahead of us in terms of commercialization, as well as our expanded capacity to conduct global clinical trials that will help move our development pipeline forward, building substantial value for our stakeholders. We look forward to sharing our achievement with you as we continue to execute our long-term growth strategy.

31:57 We would now be happy to take your questions. Thank you. Thank you. At this time, we'll be conducting a question and answer session. If you would like to ask a question, please press star 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you'd like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star key. One moment, please, while we poll for questions. Your first question comes from the line of Lay Wang with JP Morgan. Please proceed with your question.

32:52 Thank you for taking my questions and congratulations on the progress. So my first question is, can you give us some more clarity on when you might be meeting with the FDA for the ARAXO filing? And secondly, with regard to the San Antonio case, oral presentation, I think you mentioned you will have full details on the August data. I was wondering whether there are any chances for us to see more updated data, especially with regard to PFS or OS.

33:37 And then maybe lastly, can you comment on, you mentioned the potential filings in other regions, maybe you can help us to understand the regulatory strategy there and whether you might need to look for partners to explore the further opportunities out there. And thank you.

34:08 So Rudolph here. Let me answer your three questions. The first one is regarding the update on the process with the FDA on Oraxel. And I can tell you we are actively engaging with the FDA on Oroplacatexel, and we are on track with our preparations for NDA submission first quarter 2020. Your second question is what data regarding phase three trial would you expect to see in San Antonio? And we definitely intend to present a fuller data set from the top-line Phase III results announced in August. Some examples of those fuller data sets would include the standards like demography, subgroup analysis, detailed safety profile, et cetera.

35:03 We believe we have a very compelling data set to present to the physician community as well as to all of you. We are planning to, although you haven't asked it, but you are alluding to we are looking at further data on OS or PFS as we previously alluded to. I will reinforce what we have said all along, that we are planning to seek guidance from the FDA before defining new PFS and OS data cutoffs. So we cannot comment on when this will be ready for presentation at San Antonio or not at this time point. Our objective is to ensure that the best outcome from a regulatory and commercialization perspective.

35:54 Got it. So the last question is regarding regulatory outside the U.S., right? And we are in active planning and discussion regarding Other territories, of course, EU is the most important one. China, Taiwan, and New Zealand are all regulatory authorities we are targeted to discuss with.

36:25 Okay, great. And in those regions, do you plan to look for partners or you're going to do it on your own?

36:36 We are exploring all opportunities. Certainly, there are advantages and pros in terms of having partners. At the same time, we want to make sure that we will be able to capture the maximum opportunity of return for our stakeholders. We do have a lot of experience in these regions as well, and based on the vast experience that our management team, we have. And therefore, we do have different options to explore these territories.

37:07 Okay, that's very helpful. Thank you very much. Thank you. Your next question comes from the line of Kenan McKay with RBC Capital Markets. Please proceed with your question.

37:24 Hi, thank you for taking the question. Now that we're three months to the day, actually, after your Positive or Axel Phase 3 top-line data announcement, Can you help us understand what the regulatory interactions have been so far? I really do imagine that at this point you've reached out to the FDA for a meeting, but the FDA has, I think, 30 days or maybe further to respond and a further window for scheduling. Can you just help us understand if an initial meeting has taken place yet or if one has been scheduled, I ask because to Rudolph's point, it sounded like the potential to see unblinded PFS and OS data at San Antonio might be dependent on FDA feedback, evaluating some of these secondary endpoints and ways of doing this in a statistically rigorous manner moving forward. And then a second question on the regulatory pathway. I just wanted to confirm that the FDA's initial endorsement of this initial trial design being sufficient for regulatory approval was based strictly on the primary endpoint of ORR and not dependent on PFS or OS, given these were secondaries. Then I had a quick follow-up on strategic options as well.

38:44 Thank you, Kennan. As we indicate, we are actively engaging the FDA in communications, in discussion, regarding the ORAXO submission, and we are on track to file first quarter. I think I will leave it at that point. I will also point you to the fact that we don't normally communicate, FDA communications, as you may have noticed, for our turbulent program. We complete our pre-NDA consultation, and we did not announce that. That was just one of the processes We take pride in achieving the submission target.

39:29 So we'll announce our submission. I definitely will do that. The file or data regarding the San Antonio, again, it will depend on the feedback we shall receive from the FDA regarding the endpoint. And to put it again on the record, our previous dialogue with the FDA consultation is based on the primary endpoint of response rate. The PFS and OS are secondary endpoints, and they are not a requirement for the FDA consideration. Does that answer your question?

40:11 Yep, very helpful. Rudolf, thank you very much for that. Maybe just a follow-up then on strategic options here and potential for maybe bringing in some non-dilutive capital. You have a lot going on with several regulatory submissions approaching. Can you maybe just remind us of geographies where you retained ownership of KX01? I think Oceana was one of these where actinic keratosis is the most prevalent and one of the largest AK markets. And if this could be a potential option for, if licensing here could be a potential option for bringing in some non-dilutive capital, or if there are any other options out there that maybe we should be thinking about. Thanks again for taking the questions, and looking forward to San Antonio.

41:03 The KX01 or tapenadoline compound was sexually discovered and developed by Apenex, so we own the global right. Our partnership with Amro, they have acquired the right to license the rights to Europe, to U.S., not excluding Canada and Mexico, and also with Russia. So we own all the other global territories apart from these three areas. Now, and obviously, your question with regard to whether there are other opportunities in terms of non-digital capital with other geographic regions for this compound, what I would like to say is that We would like to explore all opportunities that are beneficial in creating value for our stakeholders.

41:54 Now certainly we have two successful phase three results assets and therefore you can contemplate that there are quite a number of opportunities lying in front of us and our job is to ensure that we capture the value. Certainly it will be inappropriate for us to provide details while we're evaluating these opportunities and discussions are actively ongoing. And thank you for your question. Your next question comes from the line of Kevin DeGieter with Oppenheimer. Please proceed with your question.

42:35 Thanks for taking my questions. Maybe two for me. First off, can you just comment on preparations for CMC for the oral paclitaxel NDA submission in the first quarter of 2020, specifically any outstanding steps that will need to be completed to file that portion of the submission?

43:02 With regard to your first question, we're actively preparing for the submission of the CMC sections. As indicated to you that we are contemplating that to be a very important product with a substantial market potential. So on top of resolving all the logistics and the API and then the the product manufacturing. We are also looking into Plan B and Plan C vis-a-vis. We have both the primary supplier that is ourselves. We also have backup and alternative suppliers to ensure that when we are able to launch a product, there will be no interruptions. All these activities are actively ongoing. And Dr. and Mr. Jeff Yoden and myself are actively engaging to ensure that all these processes are smooth and there will be no interruptions to our success.

43:56 I hope that this answers your first question.

43:59 Sure. And my second question actually pertains to, I believe, comments that Jeff made in his prepared remarks with regard to initial outreach and payer research, and perhaps you can elaborate a bit more in terms of the aspects of the oral paclitaxel product profile that resonated most strongly with some of the payers in that initial outreach.

44:29 Jeff? Yeah, this would be happy to do that. The feedback we've had in about three different forums that we've held was that we're very encouraged that our pricing targets look to be acceptable. We are pricing similar to the original Abraxas pricing, and the feedback has been very positive. So we're encouraged that based on our forecast and based on the selling price, we look like we're in very good shape.

45:07 Great. That's very helpful. I'll get back in the queue. Thank you. Thank you. Thank you. As a reminder, if you would like to ask a question, please press star 1 on your telephone keypad. As a reminder, if you would like to ask a question, please press star 1 on your telephone keypad. One moment, please, while we poll for more questions. Your next question comes from the line of Chad Messer with Need a Moon Company. Please proceed with your question.

45:42 Great. Thanks for taking my question and let me add my congratulations on all the progress. I also am certainly very excited for San Antonio. Maybe just one for Rudolph to start. Kind of looking forward, what is your sense of the regulatory strategy for getting, you know, for getting Araxol into other indications. You've got some interesting additional studies run. You're calling all of phase one or two, kind of wondering if you think any of those might support label expansions. And also, do you think you have to do this piecemeal in each individual indication, or is there some level of evidence you could provide that Waraxol is basically a better Paclitaxel and could be used anywhere it's used.

46:38 Thank you, Chad. You're quite right. Waraxol is based on a known molecule, Praclitaxel, which has been studied intensively and is widely used in multiple types of cancer types and multiple scenarios. So the possibility, in a sense, is like endless. If you look at the number of publications on ibuprofen, it's probably well over 1,000, 6,000, 7,000. So our strategy, as I always articulate, is to leverage that rather than repeating that. And I think in terms of showing the comparison with IV Placatexel, we choose the monotherapy as a comparison, and you will be seeing the compelling data from St. Antonio when you see the full data set.

47:39 And I think we clearly differentiate that from IV Placatexel with the strong, no one else has shown it so far with the taxin, of a lower neuropathy in the presence of a better efficacy. So this is a very, very compelling piece of data that we will leverage to expand into other indications. The first obvious one is to enhance the image of the efficacy of Pracatexel and especially Orexil in very difficult treat cancer types like angiosarcoma, cutaneous angiosarcoma. And you are seeing that we have been reporting very rapid progress in enrollment in a very, very rare disease, and this is because of the primary investigators, the principal investigators' enthusiasm of the data. So I'll leave at that. You've seen some early data.

48:41 You should expect to see continuing excitement for that indication. We also got the EU data. approval for orphan drug indication for soft tissue sarcoma, which includes angiosarcoma. And therefore, everyone is excited about that, so stay tuned. You'll see some of those data coming in the future. In terms of other indications, we have already alluded to a combination of immunotherapy and anti-REGIF, which are products, and those will be announced as the data become more mature. So certainly we're expanding into all other indications and we'll leverage whatever has been used for Placatexel and build further better than the original IV Placatexel.

49:31 In terms of regulatory, again, we're focusing in the U.S. and then we'll continue to do other indications and also other areas, building on metastatic breast cancer, and leveraging angiosarcoma and other indications as they become mature.

49:53 Oh, great. Thank you for that. And maybe one for Jeff. You talked about some of the market research you're doing in preparation for the launch and that you think you'll be initially targeting early adopter physicians and sort of hands-on types of patients. Can you talk a little bit more about that? Is this, you know, Does this mean we're going to be targeting the larger centers of excellence and maybe trying to get some information out to the consumers, internet or ads? How do you go about getting that segment of early adopter proactive patients and doctors?

50:38 Sure, Chad. It's interesting. Things are getting so sophisticated now that We have access to incredible data that gives us profiles of these physicians. And really, the best way to look at it is we're going after the physicians that we know will be most responsive to this type of therapy. And as we make progress with those physicians, it'll trickle down to others. So we have a very specific group of physicians that we've already targeted and identified, and our first marketing programs will be to those physicians. And then we move to a second set and then eventually the third set.

51:28 So I hope that answers your question.

51:31 Yeah, thanks, and congrats again, guys. Thank you. Your next question comes from the line of Yael Jen with Laidlaw and Company. Please proceed with your question.

51:47 Good morning, and thanks for taking the questions. The first question I have is that some of the investors have asked whether the Orotaxel, if you compare with, let's say, the weekly IV Taxel regimens, Do you see any benefit of the Orotaxil, particularly in the safety side, to that?

52:17 Yes. Clearly, the major benefit is they don't have to come for weekly infusion, make a trip to the infusion center. But since you're asking about safety, then definitely you will see that we have announced already that it's a significant benefit in neuropathy. And if you look at the literature carefully, neuropathy, dose-limiting neuropathy, we are talking about grade three, grade four, and above. You look at the literature, everywhere you see is a dose-limiting toxicity for all IV placatexel, all IV placatexel dosing regimen, and especially in weekly infusion. So I think we have a major significant advantage in that aspect to differentiate our cells from weekly IV Placatexel.

53:18 So do come to San Antonio. You'll see the whole data set.

53:24 Okay, great. That's very helpful. Maybe one follow-up here, which is that it might be a little bit too early, but you have mentioned about the payer research. So is there any additional color you guys might be provide at this sort of early stage of the sort of commercialization process?

53:49 Jeff? Yes. A couple of things. One, the original plan was to be looking at pricing equivalent to a Braxen pricing. and also get a very good idea about the argument that the generic tax all costs this much, and would payers be willing to pay? And because of the advantages, the inherent advantages of our product, we're very encouraged to say that, yeah, the Braxane pricing seems to be one that's going to be widely accepted by most payers. So It's early, but we're very encouraged by that data.

54:37 Okay, great. That's very, very helpful. Maybe just tackle one more question. You mentioned that you are seeking the FDA guidance in terms of the cutoff time for the progression-free as well as OS overall survival times. I'm just curious about whether you think you might get any feedback from the agency prior to the San Antonio meeting or that's, again, difficult to tell at this moment.

55:07 Yeah. As I said, we cannot dictate when the FDA will answer that specific secondary endpoint question. The specific question we would want to get clarified is about Since it's not pre-specified in the protocol, it's a pleasant surprise upside as a secondary endpoint that we're seeing a strong trend. What would be acceptable to put it in the final analysis, now to put it into the analysis plan? So we want to have more clarity from the FDA before we actually implement that, because that will be very important for our regulatory strategy and the labeling perspective.

55:55 I will leave it at that.

55:58 Okay, great. That's very, very helpful. Again, congrats, and I look forward to see the next data update.

56:06 Yeah, I just want to give you an update in terms of your second question. You obviously can anticipate that we will be conducting a pharmacoeconomic study with regard to the value of our product. in terms of the value that we are providing to both patients as well as the payers and all this obviously will very much support the proposition that we're proposing to both the patients as well as the payers. So I think all these are important considerations that you may want to have in your mind with regard to how we're going to approach launching our product and certainly We have vast experience in launching products within our team in terms of both clinical development, post-approval support, as well as marketing and sales. I think that, sort of, highly to you with regard to the fact that we are well prepared to launch this product successfully.

57:01 Thank you.

57:04 Okay, great. And that's, again, very, very helpful. Appreciate that. Thank you. Ladies and gentlemen, we have reached the end of the question-and-answer session, and I would like to turn the call back to Dr. Johnson Lau, CEO, for closing remarks.

57:22 Thank you, everyone, for your time this morning. We have made significant progress in continuing to advance towards major catalysts. For those who are interested in our oral practical and sacral data, would like to strongly encourage you to join us in the upcoming San Antonio Breast Cancer Symposium. The presentation will be in the afternoon on December 13th, and we'll have a good presence as well as inviting you to join our booth. For those who will not be able to attend the meeting, we'll be able to provide you updates after the meeting, and therefore we'll ensure that all of you are updated with regard to the progress and also the preparation work that will prepare to launch this very important product. Thank you again for your time.

58:14 This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.

Follow Athenex Inc into a list and get an email when it puts out news.

Companies on this call

Speakers

Tim McCarthy

Host, LifeSci Advisors

Lay Wang

Analyst, J.P. Morgan

Kenan McKay

Analyst, RBC Capital Markets

Chad Messer

Analyst, Needham & Company

Yael Jen

Analyst, Laidlaw & Company

Kevin DeGieter

Analyst, Oppenheimer

Dr. Johnson Lau

Chief Executive Officer

Dr. Rudolph Kwan

Chief Medical Officer

Randall Zee

Chief Financial Officer

Jeff Yorden

Chief Operating Officer

More from Athenex Inc